Identification

Name
Ibuprofen
Accession Number
DB01050  (APRD00372)
Type
Small Molecule
Groups
Approved
Description

Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.

Structure
Thumb
Synonyms
  • (±)-2-(p-isobutylphenyl)propionic acid
  • (±)-ibuprofen
  • (±)-p-isobutylhydratropic acid
  • (±)-α-methyl-4-(2-methylpropyl)benzeneacetic acid
  • (4-isobutylphenyl)-α-methylacetic acid
  • (RS)-ibuprofen
  • 2-(4-isobutylphenyl)propanoic acid
  • 4-isobutylhydratropic acid
  • Ibuprophen
  • α-(4-isobutylphenyl)propionic acid
  • α-(p-isobutylphenyl)propionic acid
Product Ingredients
IngredientUNIICASInChI Key
Ibuprofen aluminumD0YGZ1VO1B61054-06-6QAZIXAUMDFPQRW-UHFFFAOYSA-K
Ibuprofen lysineN01ORX9D6S57469-77-9IHHXIUAEPKVVII-ZSCHJXSPSA-N
Ibuprofen potassium48304089JJ79261-49-7XJELUCTZEAQYGF-UHFFFAOYSA-M
Ibuprofen sodiumRM1CE97Z4N527688-20-6VTGPMVCGAVZLQI-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-ibuprofen Tab 600mgTablet600 mgOralAltimed Pharma Inc.1984-12-311999-09-17Canada
CaldolorInjection800 mg/8mLIntravenousCumberland Pharmaceuticals2009-06-11Not applicableUs
CaldolorSolution100 mgIntravenousAlveda Pharmaceuticals Inc2012-06-15Not applicableCanada
Ibuprofen LysineSolution10 mg/mLIntravenousPrasco, Laboratories2016-04-14Not applicableUs
Ibuprofen-600 Tab 600mgTablet600 mgOralPro Doc Limitee1986-12-312014-07-24Canada
Motrin Tablets 600mgTablet600 mgOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1980-12-312004-07-22Canada
NeoProfenSolution10 mg/mLIntravenousRecordati Rare Diseases Inc2006-04-13Not applicableUs
Novo-profenTablet600 mgOralTeva1985-12-31Not applicableCanada
Nu-ibuprofen Tab 600mgTablet600 mgOralNu Pharm Inc1993-12-312012-09-04Canada
PedeaInjection, solution5 mg/mlIntravenousOrphan Europe S.A.R.L.2004-07-29Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlivioTablet800 mg/800mgOralAlivio Medical Products, Llc2015-07-012017-11-04Us
AlivioTablet400 mg/400mgOralAlivio Medical Products, Llc2015-07-012017-11-04Us
AlivioTablet600 mg/600mgOralAlivio Medical Products, Llc2015-07-012017-11-04Us
Apo Ibuprofen Tab 600mgTablet600 mgOralApotex Corporation1984-12-31Not applicableCanada
Comfort Pac with IbuprofenKitPd Rx Pharmaceuticals, Inc.2012-09-06Not applicableUs
IbuTablet600 mg/1OralUnit Dose Services2008-11-20Not applicableUs
IbuTablet600 mg/1OralGolden State Medical Supply2014-04-22Not applicableUs
IbuTablet400 mg/1OralRed Pharm Drug, Inc.2008-11-20Not applicableUs
IbuTablet400 mg/1OralNucare Pharmaceuticals, Inc.2008-11-20Not applicableUs
IbuTablet800 mg/1OralDirectrx2015-12-29Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Childrens IbuprofenSuspension100 mg/5mLOral7 Eleven2014-08-05Not applicableUs
7 Select IbuprofenTablet, film coated200 mg/1Oral7 Eleven2014-08-07Not applicableUs
7 Select IbuprofenTablet, coated200 mg/1Oral7 Eleven2014-05-13Not applicableUs
Actiprofen - Caplet 200mgTablet200 mgOralBayer Inc Consumer Care1996-12-311999-11-03Canada
AdvilTablet, coated200 mg/1OralWyeth Consumer Healthcare Llc1984-05-18Not applicableUs
AdvilCapsule, liquid filled200 mg/1OralWyeth Consumer Healthcare Llc1995-04-10Not applicableUs
AdvilCapsule, liquid filled200 mg/1OralWyeth Consumer Healthcare Llc1995-04-10Not applicableUs
AdvilTablet, coated200 mg/1OralWyeth Consumer Healthcare Llc1984-05-18Not applicableUs
AdvilTablet, coated200 mg/1OralWyeth Consumer Healthcare Llc1984-05-18Not applicableUs
AdvilTablet, coated200 mg/1OralLil' Drug Store Products, Inc.2010-02-22Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Circle K IbuprofenTablet, coated200 mg/1OralLil' Drug Store Products, Inc.2015-01-10Not applicableUs
Circle K IbuprofenTablet, coated200 mg/1OralLil' Drug Store Products, Inc.2015-01-10Not applicableUs
IbuprofenTablet200 mg/1OralAurohealth LLC2017-11-08Not applicableUs
IbuprofenTablet200 mg/1OralCardinal Health2011-06-02Not applicableUs
IbuprofenCapsule, liquid filled200 mg/1OralASSURED / DOLLAR TREE (Greenbrier International, Inc.)2017-10-31Not applicableUs
IbuprofenTablet, film coated600 mg/1OralAphena Pharma Solutions Tennessee, Inc.2009-06-10Not applicableUs
IbuprofenTablet200 mg/1OralAurohealth LLC2017-11-08Not applicableUs
IbuprofenTablet200 mg/1OralPura Cap Pharmaceutical Llc.2017-11-09Not applicableUs
IbuprofenTablet200 mg/1OralCVS Health2017-11-09Not applicableUs
IbuprofenCapsule, liquid filled200 mg/1OralPura Cap Pharmaceutical Llc.2017-11-01Not applicableUs
International/Other Brands
Act-3 (Healthcare Logistics) / Actiprofen (Sterling Health) / Adex (Dexxon) / Adran / Aktren (Bayer) / Alges-X (Axapharm) / Algoflex (Chinoin) / Algofren (Intermed) / Alivium (Bristol-Myers Squibb) / Artofen (Teva) / Betagesic (Adcock Ingram Pharmaceuticals) / Betaprofen (Be-Tabs Pharmaceuticals) / Bluton / Bonifen (Krka) / Brufen (Abbott) / Buburone (Towa Yakuhin) / Bugesic / Buprovil / Burana (Orion) / Butylenin / Calprofen (McNeil) / Cap-Profen (PERRIGO) / Children's Elixsure (Pfizer) / Children's Ibuprofen (Pfizer) / Dalsy (Abbott) / Dismenol (Merz) / Diverin / Dolgirid / Dolgit (Dolorgiet) / Dolofort / Doloraz / Dolormin / Dorival / Ebufac / EmuProfen / Epobron / Espidifen / Eve / Femadon / Fenbid / Fenpaed / Finalflex / Galprofen / Haltran / Herron Blue / i-profen / Ibalgin / Ibu-Attritin / IBU-Ratiopharm / Ibu-Vivimed / Ibuflam / Ibugel / Ibugesic / IbuHEXAL / Ibuleve / Ibum / Ibumax / Ibumetin / Ibumidol / Ibupain / Ibuprocin / Ibuprom / Ibuprosyn / Ibuprox / Ibustar / Ibutid / Ibux / Ibuxin / Inabrin / Inoven / Ipren / Junior Strength Motrin / Kratalgin / Lamidon / Lebrufen / Liptan / Lotem / Medicol / Medipren / Midol IB / Motrin / Mynosedin / Mypaid / Myprodol / Narfen / Naron Ace / Neobrufen / Nobfen / Nobgen / Norvectan / Nuprin / Nureflex / Nurofen / Orbifen / Panafen / Pediaprofen / Perifar / Profin / Ranfen / Rapidol / Ratiodolor / Rimafen / Roidenin / Rufen / Salvarina / Seclodin / Solpaflex / Speedpain NANO / Spidifen (Zambon) / Suspren / Tabalon / Tefin / Trendar / Unafen / Upfen / Urem
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
10 Person ANSIIbuprofen + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-24Not applicableUs
25 Person ANSIIbuprofen + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-25Not applicableUs
50 Person ANSIIbuprofen + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-06-02Not applicableUs
7 Select Ibuprofen PMIbuprofen (200 mg/1) + Diphenhydramine citrate (38 mg/1)Tablet, coatedOral7 Eleven2014-08-05Not applicableUs
7-Select Advil PMIbuprofen (200 mg/1) + Diphenhydramine citrate (38 mg/1)Tablet, coatedOralLil' Drug Store Products, Inc.2011-06-01Not applicableUs
Advil Allergy and Congestion ReliefIbuprofen (200 mg/1) + Chlorpheniramine maleate (4 mg/1) + Phenylephrine hydrochloride (10 mg/1)Tablet, coatedOralPfizer2012-07-23Not applicableUs
Advil Allergy and Congestion ReliefIbuprofen (200 mg/1) + Chlorpheniramine maleate (4 mg/1) + Phenylephrine hydrochloride (10 mg/1)TabletOralNavajo Manuracturing Company2016-09-16Not applicableUs
Advil Allergy SinusIbuprofen (200 mg/1) + Chlorpheniramine maleate (2 mg/1) + Pseudoephedrine hydrochloride (30 mg/1)Tablet, coatedOralPfizer2002-12-20Not applicableUs
Advil Back PainIbuprofen (200 mg) + Methocarbamol (500 mg)TabletOralPfizer Laboratories Div Pfizer Inc.Not applicableNot applicableCanada
Advil Cold & FluIbuprofen (200 mg) + Diphenhydramine citrate (38 mg)TabletOralPfizer Laboratories Div Pfizer Inc.2011-10-27Not applicableCanada
Categories
UNII
WK2XYI10QM
CAS number
15687-27-1
Weight
Average: 206.2808
Monoisotopic: 206.13067982
Chemical Formula
C13H18O2
InChI Key
HEFNNWSXXWATRW-UHFFFAOYSA-N
InChI
InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
IUPAC Name
2-[4-(2-methylpropyl)phenyl]propanoic acid
SMILES
CC(C)CC1=CC=C(C=C1)C(C)C(O)=O

Pharmacology

Indication

For symptomatic treatment of rheumatoid arthritis, juvenile rheumatoid arthritis and osteoarthritis. May be used to treat mild to moderate pain and for the management of dysmenorrhea. May be used to reduce fever. Has been used with some success for treating ankylosing spondylitis, gout and psoriatic arthritis. May reduce pain, fever and inflammation of pericarditis. May be used IV with opiates to relieve moderate to severe pain. Ibuprofen lysine may be used IV to treat patent ductus arteriosus (PDA) in premature neonates.

Structured Indications
Pharmacodynamics

Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, which are thought to act through inhibition of prostaglandin synthesis.

Mechanism of action

The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1Not AvailableHuman
UApoptosis regulator Bcl-2
modulator
Human
UThrombomodulin
modulator
Human
UTissue-type plasminogen activator
negative modulator
Human
UFatty acid-binding protein, intestinal
binder
Human
UPeroxisome proliferator-activated receptor gamma
activator
Human
UCystic fibrosis transmembrane conductance regulator
inhibitor
Human
USolute carrier family 15 member 1Not AvailableHuman
UPeroxisome proliferator-activated receptor alpha
activator
Human
Absorption

~ 80% absorbed from GI tract

Time to reach peak plasma concentration = 47 minutes (suspension), 62 minutes (chewable tablets), 120 minutes (conventional tablets)

Volume of distribution
Not Available
Protein binding

90-99% to whole human plasma and site II of purified albumin, binding appears to be saturable and becomes non-linear at concentrations exceeding 20 mcg/ml.

Metabolism

R-enanatiomer undergoes extensive enantiomeric conversion (53-65%) to the more active S-enantiomer in vivo. Metablized by oxidation to 2 inactive metabolites: (+)-2[4´-(2-hydroxy-2-methylpropyl)phenyl]propionic acid and (+)-2-[4´-(2-carboxypropyl)phenyl]propionic acid. Very small amounts of 1-hydroxyibuprofen and 3-hydroxyibuprofen have been recovered from urine. Cytochrome P450 2C9 is the major catalyst in the formation of oxidative metabolites. Oxidative metabolites may be conjugated to glucuronide prior to excretion.

Route of elimination

Ibuprofen is rapidly metabolized and eliminated in the urine.

Half life

2-4 hours

Clearance
Not Available
Toxicity

Side effects: May cause peripheral edema and fluid retention. Use caution in patients with congestive heart failure or severe uncontrolled hypertension. May cause dyspepsia, heartburn, nausea, vomiting, anorexia, diarrhea, constipation, stomatitis, flatulence, bloating, epigastric pain, and abdominal pain. Peptic ulcer and GI bleeding have been reported. May also cause dizziness, headache and nervousness. Acute renal failure accompanied by acute tubular necrosis has been reported.

Most common symptoms of overdose are abdominal pain, nausea, vomiting, lethargy, vertigo, drowsiness (somnolence), dizziness and insomnia. Other symptoms of overdose include headache, loss of consciousness, tinnitus, CNS depression, convulsions and seizures. May rarely cause metabolic acidosis, abnormal hepatic function, hyperkalemia, renal failure, dyspnea, respiratory depression, coma, acute renal failure, and apnea (primarily in very young pediatric patients).

LD50=1255mg/kg(orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ibuprofen Action PathwayDrug action
Ibuprofen Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabIbuprofen may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Ibuprofen can be increased when it is combined with Abiraterone.Approved
AcebutololIbuprofen may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Acemetacin.Approved
AcenocoumarolIbuprofen may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibuprofen.Approved, Vet Approved
AclarubicinIbuprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Ibuprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alendronic acid.Approved
AliskirenIbuprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alminoprofen.Experimental
AlprenololIbuprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Ibuprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Amcinonide.Approved
AmikacinIbuprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideIbuprofen may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Ibuprofen can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinIbuprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodIbuprofen may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Anisodamine.Investigational
annamycinIbuprofen may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Antipyrine.Approved
Antithrombin III humanIbuprofen may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanIbuprofen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Apocynin.Investigational
ApramycinIbuprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Ibuprofen can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinIbuprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinIbuprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanIbuprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArmodafinilThe metabolism of Ibuprofen can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololIbuprofen may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Atamestane.Investigational
AtenololIbuprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibuprofen.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ibuprofen.Approved
BalsalazideIbuprofen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminIbuprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololIbuprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinIbuprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Ibuprofen.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ibuprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ibuprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololIbuprofen may decrease the antihypertensive activities of Betaxolol.Approved
BevantololIbuprofen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ibuprofen.Approved, Investigational
BisoprololIbuprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinIbuprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololIbuprofen may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Ibuprofen can be decreased when combined with Bortezomib.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibuprofen.Approved
BucillamineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Bucillamine.Investigational
BucindololIbuprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Bufexamac.Experimental
BufuralolIbuprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Bumadizone.Experimental
BumetanideIbuprofen may decrease the diuretic activities of Bumetanide.Approved
BupranololIbuprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Ibuprofen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ibuprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ibuprofen.Experimental
CapecitabineThe metabolism of Ibuprofen can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Ibuprofen.Approved
CarbamazepineThe metabolism of Ibuprofen can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ibuprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ibuprofen.Approved, Vet Approved, Withdrawn
CarteololIbuprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolIbuprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Ibuprofen can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololIbuprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ibuprofen can be increased when it is combined with Ceritinib.Approved
CertoparinIbuprofen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloramphenicolThe metabolism of Ibuprofen can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ibuprofen.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuprofen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ibuprofen.Approved
CholecalciferolThe metabolism of Ibuprofen can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ibuprofen.Approved
CimetidineThe metabolism of Ibuprofen can be decreased when combined with Cimetidine.Approved
CinoxacinIbuprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Ibuprofen can be decreased when combined with Citalopram.Approved
Citric AcidIbuprofen may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ibuprofen.Vet Approved
CloranololIbuprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Ibuprofen can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Ibuprofen can be decreased when combined with Crisaborole.Approved
CurcuminThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ibuprofen.Experimental
CyclosporineIbuprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with D-Limonene.Investigational
Dabigatran etexilateIbuprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ibuprofen can be decreased when it is combined with Dabrafenib.Approved
DalteparinIbuprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidIbuprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanIbuprofen may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinIbuprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Ibuprofen can be increased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Ibuprofen.Experimental
DelavirdineThe metabolism of Ibuprofen can be decreased when combined with Delavirdine.Approved
DesirudinIbuprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Ibuprofen.Approved, Investigational
DextranIbuprofen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Ibuprofen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Ibuprofen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Ibuprofen may increase the anticoagulant activities of Dextran 75.Approved
DibekacinIbuprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ibuprofen.Approved, Vet Approved
DicoumarolIbuprofen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibuprofen.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ibuprofen.Approved
DihydrostreptomycinIbuprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Ibuprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ibuprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Ibuprofen.Approved
DosulepinThe metabolism of Ibuprofen can be decreased when combined with Dosulepin.Approved
DoxorubicinIbuprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneIbuprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Ibuprofen is combined with E-6201.Investigational
Edetic AcidIbuprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanIbuprofen may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Ibuprofen can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Ibuprofen.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ibuprofen.Approved
EnoxacinIbuprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinIbuprofen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Ibuprofen.Experimental
EpanololIbuprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Epirizole.Approved
EpirubicinIbuprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneIbuprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ibuprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ibuprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Equilin.Approved
Eslicarbazepine acetateThe metabolism of Ibuprofen can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololIbuprofen may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Ibuprofen can be decreased when combined with Esomeprazole.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Estrone sulfate.Approved
Etacrynic acidIbuprofen may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Ibuprofen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateIbuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Ibuprofen.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Ibuprofen can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Ibuprofen is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Felbinac.Experimental
FelodipineThe metabolism of Ibuprofen can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibuprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Ibuprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Feprazone.Experimental
Ferulic acidIbuprofen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ibuprofen.Approved, Investigational
FleroxacinIbuprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Ibuprofen.Approved, Withdrawn
FloxuridineThe metabolism of Ibuprofen can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with fluasterone.Investigational
FluconazoleThe metabolism of Ibuprofen can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fludrocortisone.Approved
FluindioneIbuprofen may increase the anticoagulant activities of Fluindione.Investigational
FlumequineIbuprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Ibuprofen can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Ibuprofen can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Ibuprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibuprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Ibuprofen can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Ibuprofen can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ibuprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxIbuprofen may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumIbuprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Ibuprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ibuprofen.Approved
FosphenytoinThe metabolism of Ibuprofen can be increased when combined with Fosphenytoin.Approved
FramycetinIbuprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideIbuprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateIbuprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinIbuprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinIbuprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Ibuprofen.Approved, Withdrawn
GemfibrozilThe metabolism of Ibuprofen can be decreased when combined with Gemfibrozil.Approved
GemifloxacinIbuprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinIbuprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinIbuprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AIbuprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Ibuprofen may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinIbuprofen may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Ibuprofen is combined with HE3286.Investigational
HeparinIbuprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Higenamine.Investigational
HydralazineIbuprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ibuprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ibuprofen.Approved, Investigational
Hygromycin BIbuprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ibandronate.Approved, Investigational
IbuproxamThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Icatibant.Approved
IdarubicinIbuprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxIbuprofen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ibuprofen.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Ibuprofen.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Ibuprofen.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuprofen.Approved
IndenololIbuprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Ibuprofen can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibuprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Indoprofen.Withdrawn
INNO-206Ibuprofen may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Ibuprofen can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinIbuprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoniazidThe metabolism of Ibuprofen can be decreased when combined with Isoniazid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Istaroxime.Investigational
KanamycinIbuprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Ibuprofen can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ibuprofen.Approved
LabetalolIbuprofen may decrease the antihypertensive activities of Labetalol.Approved
LandiololIbuprofen may decrease the antihypertensive activities of Landiolol.Investigational
LapatinibThe metabolism of Ibuprofen can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ibuprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Ibuprofen.Approved, Investigational
LeflunomideThe metabolism of Ibuprofen can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinIbuprofen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanIbuprofen may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololIbuprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinIbuprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Ibuprofen.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ibuprofen.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Ibuprofen.Approved
LobeglitazoneThe metabolism of Ibuprofen can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lonazolac.Experimental
LopinavirThe metabolism of Ibuprofen can be increased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Ibuprofen can be decreased when combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Loteprednol.Approved
LovastatinThe metabolism of Ibuprofen can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ibuprofen.Approved, Investigational
LuliconazoleThe serum concentration of Ibuprofen can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ibuprofen can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Ibuprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Ibuprofen can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ibuprofen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Ibuprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuprofen.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibuprofen.Approved
MelagatranIbuprofen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibuprofen.Approved, Vet Approved
MepindololIbuprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineIbuprofen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Metamizole.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ibuprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololIbuprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuprofen.Approved
MetoprololIbuprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideIbuprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinIbuprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Ibuprofen can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Ibuprofen can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ibuprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Ibuprofen can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Ibuprofen can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Ibuprofen.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ibuprofen.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibuprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibuprofen.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ibuprofen.Approved
NadololIbuprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinIbuprofen may increase the anticoagulant activities of Nadroparin.Approved
NafamostatIbuprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Ibuprofen.Approved
Nalidixic AcidIbuprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ibuprofen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Ibuprofen is combined with NCX 1022.Investigational
NeamineIbuprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololIbuprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NelfinavirThe metabolism of Ibuprofen can be decreased when combined with Nelfinavir.Approved
NemonoxacinIbuprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinIbuprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ibuprofen.Approved
NetilmicinIbuprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Ibuprofen can be decreased when combined with Nicardipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Ibuprofen can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nitroaspirin.Investigational
NorfloxacinIbuprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ibuprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibuprofen.Approved
OlsalazineIbuprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Ibuprofen.Investigational
OmeprazoleThe metabolism of Ibuprofen can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Orgotein.Vet Approved
OtamixabanIbuprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibuprofen.Approved
Oxolinic acidIbuprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololIbuprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pamidronate.Approved
PantoprazoleThe metabolism of Ibuprofen can be decreased when combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Parecoxib.Approved
ParomomycinIbuprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Parthenolide.Investigational
PazufloxacinIbuprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinIbuprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololIbuprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateIbuprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateIbuprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Ibuprofen.Approved
PhenindioneIbuprofen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Ibuprofen can be increased when combined with Phenobarbital.Approved
PhenprocoumonIbuprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibuprofen.Approved, Vet Approved
PhenytoinThe metabolism of Ibuprofen can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibuprofen.Approved, Investigational
PindololIbuprofen may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Ibuprofen can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidIbuprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinIbuprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideIbuprofen may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pirfenidone.Approved, Investigational
Piromidic acidIbuprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibuprofen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pirprofen.Experimental
Platelet Activating FactorIbuprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinIbuprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinIbuprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ibuprofen.Approved
PractololIbuprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Ibuprofen.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe metabolism of Ibuprofen can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Ibuprofen can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Propacetamol.Approved, Investigational
PropranololIbuprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Ibuprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Ibuprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Ibuprofen.Vet Approved
Protein CIbuprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanIbuprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeIbuprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinIbuprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Ibuprofen is combined with PTC299.Investigational
PuromycinIbuprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Ibuprofen can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Ibuprofen.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ibuprofen.Approved
QuinineThe metabolism of Ibuprofen can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Ibuprofen can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Ibuprofen.Approved
RanolazineThe serum concentration of Ibuprofen can be increased when it is combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ibuprofen.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinIbuprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinIbuprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifampicinThe metabolism of Ibuprofen can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ibuprofen can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Risedronate.Approved, Investigational
RivaroxabanIbuprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Ibuprofen.Investigational, Withdrawn
RosiglitazoneThe metabolism of Ibuprofen can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinIbuprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinIbuprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinIbuprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Ibuprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibuprofen.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ibuprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Ibuprofen.Investigational
SecobarbitalThe metabolism of Ibuprofen can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Serrapeptase.Investigational
SertralineThe metabolism of Ibuprofen can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Ibuprofen can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinIbuprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinIbuprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Ibuprofen.Approved
SorafenibThe metabolism of Ibuprofen can be decreased when combined with Sorafenib.Approved, Investigational
SotalolIbuprofen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CIbuprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinIbuprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinIbuprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Ibuprofen.Approved
SpironolactoneIbuprofen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Ibuprofen is combined with SRT501.Investigational
StiripentolThe metabolism of Ibuprofen can be decreased when combined with Stiripentol.Approved
StreptomycinIbuprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinIbuprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Ibuprofen can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Ibuprofen can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibuprofen.Approved
SulfisoxazoleThe metabolism of Ibuprofen can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Ibuprofen.Approved
SulodexideIbuprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Ibuprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibuprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Suxibuzone.Experimental
TacrolimusIbuprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Ibuprofen.Approved
TalinololIbuprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Ibuprofen.Approved
TamoxifenThe metabolism of Ibuprofen can be decreased when combined with Tamoxifen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ibuprofen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ibuprofen.Approved, Investigational
TemafloxacinIbuprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Ibuprofen.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibuprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tepoxalin.Vet Approved
TeriflunomideThe metabolism of Ibuprofen can be decreased when combined with Teriflunomide.Approved
TertatololIbuprofen may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Ibuprofen can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Ibuprofen can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololIbuprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tixocortol.Approved
TobramycinIbuprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Ibuprofen can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibuprofen.Approved
TopiramateThe metabolism of Ibuprofen can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Ibuprofen can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideIbuprofen may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ibuprofen.Approved
TranilastThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Ibuprofen can be decreased when combined with Tranylcypromine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ibuprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ibuprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneIbuprofen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ibuprofen.Approved, Vet Approved
TrimethoprimThe metabolism of Ibuprofen can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Triptolide.Investigational
TrovafloxacinIbuprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinIbuprofen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ibuprofen.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibuprofen.Investigational, Withdrawn
Valproic AcidThe metabolism of Ibuprofen can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinIbuprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Ibuprofen can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Ibuprofen.Approved
VoriconazoleThe serum concentration of Ibuprofen can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinIbuprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranIbuprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Ibuprofen can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Ibuprofen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Ibuprofen.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinIbuprofen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinIbuprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZucapsaicinThe metabolism of Ibuprofen can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol
  • Food delays the time to reach peak plasma concentrations by 30-60 minutes and reduces peak plasma concentrations by 30-50%. Extent of absorption is unaffected.
  • Take with food to reduce gastric irritation.

References

Synthesis Reference

http://en.wikipedia.org/wiki/Ibuprofen#Synthesis

General References
  1. Zawada ET Jr: Renal consequences of nonsteroidal antiinflammatory drugs. Postgrad Med. 1982 May;71(5):223-30. [PubMed:7041104]
  2. Townsend KP, Pratico D: Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 2005 Oct;19(12):1592-601. [PubMed:16195368]
  3. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol. 2005 Dec;58(6):963-7. [PubMed:16240369]
  4. Geisslinger G, Dietzel K, Bezler H, Nuernberg B, Brune K: Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol. 1989 Jul;27(7):324-8. [PubMed:2777420]
  5. Bergner T, Przybilla B: Photosensitization caused by ibuprofen. J Am Acad Dermatol. 1992 Jan;26(1):114-6. [PubMed:1531054]
  6. Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li S: A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi: 10.1523/JNEUROSCI.5045-09.2010. [PubMed:20089905]
External Links
Human Metabolome Database
HMDB01925
KEGG Drug
D00126
KEGG Compound
C01588
PubChem Compound
3672
PubChem Substance
46507255
ChemSpider
3544
BindingDB
50009859
ChEBI
5855
ChEMBL
CHEMBL521
Therapeutic Targets Database
DAP000780
PharmGKB
PA449957
IUPHAR
2713
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ibuprofen
ATC Codes
M02AA13 — IbuprofenR02AX02 — IbuprofenC01EB16 — IbuprofenM01AE51 — Ibuprofen, combinationsM01AE01 — IbuprofenG02CC01 — Ibuprofen
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
FDA label
Download (1.77 MB)
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceCancer, Breast1
0CompletedTreatmentFracture, Ankle1
0CompletedTreatmentPrimary Dysmenorrhoea1
0Not Yet RecruitingTreatmentPostoperative pain1
0SuspendedPreventionHypertensive1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedNot AvailableBioequivalence1
1CompletedNot AvailableHealthy Volunteers8
1CompletedBasic ScienceHealthy Volunteer Study2
1CompletedBasic ScienceHealthy Volunteers5
1CompletedBasic ScienceHealthy Volunteers / Inflammatory Reaction / Pain1
1CompletedBasic ScienceInflammatory Reaction / Pain1
1CompletedBasic SciencePain4
1CompletedBasic SciencePharmacokinetics1
1CompletedDiagnosticBone destruction / Osteoarthritis (OA)1
1CompletedOtherModerate Pain1
1CompletedPreventionGastroduodenal Erosions1
1CompletedTreatmentAllergic Rhinitis (AR)1
1CompletedTreatmentBioequivalency2
1CompletedTreatmentHealthy Volunteers11
1CompletedTreatmentKnee Osteoarthritis (Knee OA)1
1CompletedTreatmentNSAID Related Gastric Irritation1
1CompletedTreatmentOsteoarthritis (OA)1
1CompletedTreatmentPain1
1CompletedTreatmentSpinal Cord Injuries (SCI)1
1RecruitingPreventionOther and unspecified effects of high altitude1
1RecruitingSupportive CareBalanitis / Paraphimosis / Phimosis / Postoperative pain1
1RecruitingTreatmentNeonates / Patent Ductus Arteriosus (PDA)1
1Unknown StatusBasic ScienceKnee Osteoarthritis (Knee OA)1
1Unknown StatusBasic ScienceOther and unspecified effects of high altitude1
1Unknown StatusTreatmentAlzheimer's Disease (AD)1
1Unknown StatusTreatmentDuchenne's Muscular Dystrophy (DMD)1
1, 2CompletedTreatmentTemporomandibular Joint Disorders1
1, 2Enrolling by InvitationPreventionAnalgesic Drugs / Pain Relief1
1, 2Unknown StatusTreatmentChoroidal Melanoma / Eye Neoplasms / Melanoma1
1, 2Unknown StatusTreatmentInfant, Extremely Premature / IV Ibuprofen / Oral Ibuprofen / Patent Ductus Arteriosus (PDA)1
2Active Not RecruitingTreatmentImpacted Wisdom Teeth1
2CompletedNot AvailableComplication Due to Immunization1
2CompletedBasic ScienceSkeletal Muscle Mass Regulation1
2CompletedSupportive CareStomatitis, Aphthous1
2CompletedTreatmentAcute Sore Throat Pain1
2CompletedTreatmentAdenoidectomy / Tonsillectomy1
2CompletedTreatmentCervical Strain1
2CompletedTreatmentContraception1
2CompletedTreatmentDelayed Onset Muscle Soreness1
2CompletedTreatmentDental Pain1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDysmenorrhea1
2CompletedTreatmentIrreversible Pulpitis / Pain / Postoperative pain1
2CompletedTreatmentMigraines1
2CompletedTreatmentOsteoarthritis (OA)1
2CompletedTreatmentPain6
2CompletedTreatmentPain, Acute1
2CompletedTreatmentPost-Operative Pain1
2CompletedTreatmentPostoperative Dental Pain1
2CompletedTreatmentPostoperative pain1
2CompletedTreatmentSoft Tissue Injury1
2Enrolling by InvitationSupportive CareGingivostomatitis / Hand, Foot, and Mouth Disease / Herpangina1
2Enrolling by InvitationTreatmentTuberculosis1
2Not Yet RecruitingSupportive CareCarpal Tunnel Syndrome (CTS) / Cystic tumour of the ganglia / De Quervain's Disease / Dupuytren's Contracture / Trigger Digit1
2Not Yet RecruitingTreatmentConcussion, Brain1
2Not Yet RecruitingTreatmentPain Management1
2Not Yet RecruitingTreatmentSunburn1
2RecruitingBasic ScienceChronic Granulomatous Disease X-linked (X-CGD)1
2RecruitingPreventionFertilization in Vitro/Methods / Ovulation / Ovulation Inhibition / Ovulation Inhibition/Drug Effects / Pregnancy1
2RecruitingPreventionPost-ERCP Acute Pancreatitis1
2RecruitingPreventionRetinopathy of Prematurity1
2RecruitingSupportive CareCognitive Impairments / Stage 0 Colorectal Cancer / Stage I Colorectal Cancer / Stage II Colorectal Cancer / Stage IIA Colorectal Cancer / Stage IIB Colorectal Cancer / Stage IIC Colorectal Cancer / Stage III Colorectal Cancer / Stage IIIA Colorectal Cancer / Stage IIIB Colorectal Cancer / Stage IIIC Colorectal Cancer1
2RecruitingTreatmentBronchopulmonary Dysplasia (BPD)1
2RecruitingTreatmentCancer-related Cognitive Difficulties1
2RecruitingTreatmentCervical Spondylosis / Lumbar Spondylosis1
2RecruitingTreatmentDelayed Onset Muscle Soreness, DOMS1
2RecruitingTreatmentDuctus Arteriosus, Patent1
2TerminatedTreatmentPost-surgical Dental Pain1
2TerminatedTreatmentPostsurgical Pain Due to Third Molar Extraction1
2Unknown StatusPreventionPost Bronchoscopy Fever1
2Unknown StatusPreventionSpectrum of Altitude-associated Neurologic Forms of Altitude1
2Unknown StatusSupportive CareMetastatic Cancers1
2Unknown StatusTreatmentImpacted Third Molar Tooth1
2WithdrawnTreatmentDental Pain1
2WithdrawnTreatmentHb-SS Disease With Vasoocclusive Pain / Hemoglobin SS Disease With Crisis / Hemoglobin SS Disease With Vasoocclusive Crisis / Other Sickle Cell Disease With Vaso-Occlusive Pain / Sickle Cell Disorders1
2WithdrawnTreatmentPatent Ductus Arteriosus (PDA)1
2, 3CompletedBasic ScienceMajor Depressive Disorder (MDD)1
2, 3CompletedSupportive CareHypertensive1
2, 3CompletedTreatmentCervicobrachial Neuralgia1
2, 3CompletedTreatmentDuctus Arteriosus, Patent1
2, 3CompletedTreatmentIdiopathic Intracranial Hypertension (IIH)1
2, 3CompletedTreatmentLow Back Pain (LBP)1
2, 3RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
2, 3RecruitingTreatmentDuctus Arteriosus, Patent / Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants1
2, 3RecruitingTreatmentPatent Ductus Arteriosus (PDA) / Respiratory Distress Syndrome (RDS)1
3Active Not RecruitingTreatmentAcute Ankle Sprain1
3Active Not RecruitingTreatmentCerebral Palsy (CP)1
3Active Not RecruitingTreatmentPatent Ductus Arteriosus (PDA)1
3CompletedNot AvailablePain1
3CompletedPreventionAcute Kidney Injury (AKI) / Exercise-associated Hyponatremia / Perceived Exertion1
3CompletedPreventionAltitude Sickness1
3CompletedPreventionChronic Low Back Pain (CLBP) / Chronic Regional Pain Syndrome / Chronic Soft Tissue Pain / Osteoarthritis (OA) / Rheumatoid Arthritis1
3CompletedPreventionIUD Removal1
3CompletedPreventionPeptic Ulcers1
3CompletedPreventionUlcers1
3CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Chronic Lung Diseases / Shock, Septic1
3CompletedTreatmentAcute Sore Throat Pain1
3CompletedTreatmentAsthma Bronchial / Wheezing1
3CompletedTreatmentDelayed Onset Muscle Soreness, DOMS1
3CompletedTreatmentDental Pain1
3CompletedTreatmentDysmenorrhea1
3CompletedTreatmentFevers3
3CompletedTreatmentFevers / Respiratory Tract Infections (RTI)1
3CompletedTreatmentForearm Fractures1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentModerate or Severe Submental Fullness1
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentPain8
3CompletedTreatmentPain / Post-Operative Pain / Third Molar Extraction1
3CompletedTreatmentPain / Pregnancy1
3CompletedTreatmentPatent Ductus Arteriosus (PDA)1
3CompletedTreatmentPost Operative Dental Pain1
3CompletedTreatmentPost-Operative Pain1
3CompletedTreatmentPost-surgical Pain Following Extraction of Molar Teeth1
3CompletedTreatmentPostoperative Dental Pain1
3CompletedTreatmentPostoperative pain1
3CompletedTreatmentPostoperative pain / Tooth Diseases1
3CompletedTreatmentPrimary Dysmenorrhoea1
3CompletedTreatmentTonsillectomy1
3CompletedTreatmentTooth Extraction Status Nos1
3CompletedTreatmentMinor burns1
3Not Yet RecruitingTreatmentCold1
3Not Yet RecruitingTreatmentFlu Symptoms2
3Not Yet RecruitingTreatmentHernia / Pain1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3RecruitingTreatmentAlzheimer's Disease (AD)1
3RecruitingTreatmentBack Pain / Cervical Pain1
3RecruitingTreatmentFevers1
3RecruitingTreatmentLong-bone Fractures / Pain1
3RecruitingTreatmentPain1
3RecruitingTreatmentPatent Ductus Arteriosus (PDA)2
3RecruitingTreatmentPost Operative Pain1
3TerminatedTreatmentDysmenorrhea1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentInfection NOS1
3TerminatedTreatmentModerate to Severe Primary Dysmenorrhea1
3TerminatedTreatmentPostoperative pain1
3Unknown StatusSupportive CarePostoperative pain1
3Unknown StatusTreatmentHeadaches1
3Unknown StatusTreatmentMuscular Atrophy / Sprains / Tendonitis1
3Unknown StatusTreatmentNeoplasms, Breast1
3Unknown StatusTreatmentPediatric Obstructive Sleep Apnea Syndrome1
3WithdrawnTreatmentOsteoarthritis (OA)1
3WithdrawnTreatmentPain1
3WithdrawnTreatmentAcute Rhinitis1
4Active Not RecruitingPreventionPain, Acute / Postoperative pain1
4Active Not RecruitingTreatmentEclampsia / HELLP Syndrome / Prophylaxis of preeclampsia1
4Active Not RecruitingTreatmentPatent Ductus Arteriosus (PDA)1
4Active Not RecruitingTreatmentPostoperative pain1
4CompletedNot AvailablePatent Ductus Arteriosus (PDA) / Prematurity of Fetus1
4CompletedBasic ScienceHealthy Volunteers2
4CompletedBasic ScienceIschaemic Heart Diseases / Osteoarthritis (OA)1
4CompletedBasic SciencePain1
4CompletedPreventionAcute Mountain Sickness, Blood Oxygen Saturation, Headache1
4CompletedPreventionArthroplasty, Replacement, Hip / Osteoarthritis, Hip / Rheumatoid Arthritis1
4CompletedPreventionOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedPreventionPain Measurement1
4CompletedPreventionRecurrence of Febrile Seizure1
4CompletedPreventionStreptococcal Infections1
4CompletedPreventionVaccines, Pneumococcal1
4CompletedSupportive CareCongenital Muscular Torticollis1
4CompletedSupportive CareOrthodontic Pain1
4CompletedSupportive CarePain1
4CompletedSupportive CarePain / Pituitary Neoplasms1
4CompletedSupportive CareSymptomatic Uterine Fibroids and Adenomyosis1
4CompletedTreatmentAcute Cystitis (Excl in Pregnancy)1
4CompletedTreatmentAlzheimer's Disease (AD)1
4CompletedTreatmentAnalgesia / Postoperative pain1
4CompletedTreatmentAnalgesics1
4CompletedTreatmentArthroscopic Knee Surgery1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentBariatric Surgery Candidate / Obesity, Morbid1
4CompletedTreatmentBreast Pain1
4CompletedTreatmentChronic Low Back Pain (CLBP)1
4CompletedTreatmentDental Pain1
4CompletedTreatmentFeeling Anxious / Nausea / Pain1
4CompletedTreatmentFevers3
4CompletedTreatmentFevers / Pain1
4CompletedTreatmentFracture Bone1
4CompletedTreatmentGallbladder disorders1
4CompletedTreatmentGastrointestinal Mucosal Damage1
4CompletedTreatmentGeneral Surgery1
4CompletedTreatmentHeadache, Tension-Type / Headaches / Tension-Type Headache (Episodic)1
4CompletedTreatmentHeat / Pain1
4CompletedTreatmentHypertensive1
4CompletedTreatmentImpaired Renal Function / Myocardial Infarction (MI) / Postoperative pain1
4CompletedTreatmentInfants, Premature / Patent Ductus Arteriosus (PDA)1
4CompletedTreatmentIrreversible Pulpitis1
4CompletedTreatmentJuvenile Idiopathic Arthritis (JIA)1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)4
4CompletedTreatmentMigrainous Headache1
4CompletedTreatmentMosquito Bites1
4CompletedTreatmentMuscle Soreness1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentOsteoarthritis of the Hip or Knee1
4CompletedTreatmentPain6
4CompletedTreatmentPain, Acute1
4CompletedTreatmentPatent Ductus Arteriosus (PDA)2
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentRotator Cuff Syndrome1
4CompletedTreatmentTraumas1
4CompletedTreatmentUrinary Tract Infections (UTIs)1
4Enrolling by InvitationTreatmentCarpal Tunnel / Cystic tumour of the ganglia / De Quervain's Disease / Trigger Finger1
4Not Yet RecruitingTreatmentAnalgesia / Percutaneous Nephrolithotomy1
4Not Yet RecruitingTreatmentAnalgesics, Opioid / Anti-Inflammatory Agents, Non-Steroidal / Child/Adolescent Problems / Emergency Service, Hospital / Fentanyl / Ibuprofen / Pain, Acute1
4Not Yet RecruitingTreatmentArthritic Knee Pain1
4Not Yet RecruitingTreatmentLow Back Pain (LBP)1
4Not Yet RecruitingTreatmentPain1
4RecruitingHealth Services ResearchPain1
4RecruitingPreventionAnaesthesia therapy / Hip Fractures1
4RecruitingSupportive CareCarpal Tunnel1
4RecruitingSupportive CareImpacted Third Molar Tooth / Other Surgical Procedures / Pain1
4RecruitingTreatmentAcute Diverticulitis1
4RecruitingTreatmentCervical Preparation / Pain / Pregnancy Termination1
4RecruitingTreatmentEpisodic Migraine1
4RecruitingTreatmentFevers / Pain1
4RecruitingTreatmentFlu caused by Influenza1
4RecruitingTreatmentHypertension, Pregnancy-Induced / Prophylaxis of preeclampsia1
4RecruitingTreatmentLow Back Pain (LBP)1
4RecruitingTreatmentLumbar Disc Disease / Lumbar Radiculopathy / Prolapsed Lumbar Disc1
4RecruitingTreatmentPain2
4RecruitingTreatmentPostoperative pain2
4RecruitingTreatmentRib Fractures / Wounds and Injuries1
4RecruitingTreatmentSciatica1
4SuspendedTreatmentRotator Cuff Syndrome1
4TerminatedTreatmentAdverse Reaction to Drug / Obstructive Sleep Apnea (OSA) / Recurrent Tonsillitis / Sleep Disordered Breathing (SDB)1
4TerminatedTreatmentDepression / Depression, Myalgia1
4TerminatedTreatmentHematologic Diseases / Sickle Cell Disorders1
4TerminatedTreatmentInflammatory Responses1
4TerminatedTreatmentPain1
4TerminatedTreatmentPatent Ductus Arteriosus (PDA)1
4TerminatedTreatmentPeriodontitis1
4TerminatedTreatmentSickle Cell Disorders1
4Unknown StatusDiagnosticPatent Ductus Arteriosus (PDA)1
4Unknown StatusSupportive CareChronic Pelvic Pain1
4Unknown StatusTreatmentDental Extraction1
4Unknown StatusTreatmentFevers3
4Unknown StatusTreatmentPharyngitis1
4WithdrawnTreatmentDuctus Arteriosus, Patent / Very Low Birth Weight Infants1
Not AvailableActive Not RecruitingTreatmentColles Fracture1
Not AvailableCompletedNot AvailableAging / Physical Fitness1
Not AvailableCompletedNot AvailableConcussions / Headaches1
Not AvailableCompletedBasic ScienceAsthma, Allergic1
Not AvailableCompletedBasic ScienceBMI >30 kg/m21
Not AvailableCompletedBasic ScienceIschemic Reperfusion Injury1
Not AvailableCompletedBasic SciencePlatelet Aggregation1
Not AvailableCompletedDiagnosticCystic Fibrosis (CF) / Diabetes Mellitus (DM)1
Not AvailableCompletedDiagnosticDermatitis, Photocontact1
Not AvailableCompletedOtherAnti Inflammatory Non-Steroidal / Cystic Fibrosis (CF) / Neutrophils1
Not AvailableCompletedPreventionCardiovascular Disease (CVD)1
Not AvailableCompletedPreventionPostoperative pain / Wisdom Tooth1
Not AvailableCompletedPreventionBone destruction / Sarcopenia1
Not AvailableCompletedSupportive CareElbow Fractures1
Not AvailableCompletedSupportive CareHyperalgesia / Ibuprofen / Postoperative pain / Remifentanil1
Not AvailableCompletedTreatmentAnalgesia Post Fracture / Upper Extremity Fractures1
Not AvailableCompletedTreatmentCancer, Breast1
Not AvailableCompletedTreatmentCystic Fibrosis (CF)2
Not AvailableCompletedTreatmentDiverticulitis1
Not AvailableCompletedTreatmentDysmenorrhea1
Not AvailableCompletedTreatmentFracture Bone1
Not AvailableCompletedTreatmentGlaucoma / Ocular Hypertension1
Not AvailableCompletedTreatmentHemophilia A / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHernia, Abdominal / Inguinal Hernias / Laparoscopic Cholecystectomy / Umbilical Hernias1
Not AvailableCompletedTreatmentHypoxic Ischemic Encephalopathy (HIE) / Perinatal Asphyxia1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)4
Not AvailableCompletedTreatmentLow Back Pain (LBP)1
Not AvailableCompletedTreatmentMusculoskeletal Injuries1
Not AvailableCompletedTreatmentPain3
Not AvailableCompletedTreatmentPatent Ductus Arteriosus (PDA)3
Not AvailableCompletedTreatmentPneumonia1
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableCompletedTreatmentSkin Laxity1
Not AvailableCompletedTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableCompletedTreatmentSpondyloarthritis, Axial1
Not AvailableCompletedTreatmentTemporomandibular Disorders1
Not AvailableEnrolling by InvitationOtherKnee Osteoarthritis (Knee OA)1
Not AvailableEnrolling by InvitationSupportive CareInfertilities / Subfertility1
Not AvailableNot Yet RecruitingTreatmentInguinal Surgery1
Not AvailableRecruitingNot AvailableMultimodal Analgesia / Nonsteroidal Anti-inflammatory Drugs1
Not AvailableRecruitingBasic ScienceStability & Variability of Lipid-derived Molecules in Sweat1
Not AvailableRecruitingPreventionCachexia / Neoplasms1
Not AvailableRecruitingPreventionDisorder of Urinary Stent / Ureteral Spasm / Ureteropelvic Junction Obstruction / Urolithiasis1
Not AvailableRecruitingPreventionImmune System and Related Disorders1
Not AvailableRecruitingTreatmentBiliary Colic1
Not AvailableRecruitingTreatmentHigh Altitude Headache / Other and unspecified effects of high altitude1
Not AvailableRecruitingTreatmentHypertension, Pregnancy-Induced1
Not AvailableRecruitingTreatmentPatent Ductus Arteriosus (PDA)2
Not AvailableRecruitingTreatmentRotator Cuff Tear Arthropathy1
Not AvailableSuspendedTreatmentLaceration / Pain1
Not AvailableTerminatedPreventionPain1
Not AvailableTerminatedTreatmentCachexia / Cancer, Advanced1
Not AvailableTerminatedTreatmentDuctus Arteriosus, Patent / Preterm Infants1
Not AvailableTerminatedTreatmentPatent Ductus Arteriosus (PDA) / Premature Babies1
Not AvailableTerminatedTreatmentSevere Traumatic Brain Injury / Subarachnoid Hemorrhage1
Not AvailableTerminatedTreatmentSoft Tissue Injury1
Not AvailableUnknown StatusNot AvailableFevers1
Not AvailableUnknown StatusBasic ScienceMalignant Neoplasm of Colon1
Not AvailableUnknown StatusPreventionOral Ibuprofen Prophylaxis in Very Low Birth Weight Infants1
Not AvailableUnknown StatusSupportive CarePrimary Post Tonsillectomy Hemorrhage / Secondary Post Tonsillectomy Hemorrhage1
Not AvailableUnknown StatusTreatmentFevers1
Not AvailableUnknown StatusTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableUnknown StatusTreatmentFracture Bone / Pain1
Not AvailableUnknown StatusTreatmentPain1
Not AvailableUnknown StatusTreatmentPleuro-pneumonia1
Not AvailableWithdrawnSupportive CareToothache1
Not AvailableWithdrawnTreatmentPsychiatric Disorder NOS1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedOral256 mg/1
Tablet, extended releaseOral600 mg
CapsuleOral
Capsule; kitOral
CapsuleOral400 mg
CapsuleOral200 mg
TabletOral400 mg/400mg
TabletOral600 mg/600mg
TabletOral800 mg/800mg
TabletOral300 mg
TabletOral600 mg
TabletOral200 mg
InjectionIntravenous800 mg/8mL
SolutionIntravenous100 mg
SuspensionOral100 mg
Tablet, chewableOral50 mg
TabletOral50 mg
LiquidOral100 mg/5mL
SolutionOral100 mg/5mL
SuspensionOral200 mg/10mL
Kit; tabletOral
Kit
KitOral; Topical
Kit
SuspensionOral
Suspension / dropsOral50 mg/1.25mL
Tablet, coatedOral200 mg/1
Tablet, film coatedOral200 mg/1
TabletOral
Capsule, liquid filledOral200 mg/1
SuspensionOral100 mg/5mL
SuspensionOral50 mg/1.25mL
Capsule, coatedOral200 mg/1
Capsule, liquid filledOral220 mg/1
TabletOral100 mg/1
TabletOral400 mg/1
TabletOral800 1/1
TabletOral800 mg/1
Tablet, coatedOral400 mg/1
Tablet, coatedOral600 mg/1
Tablet, coatedOral800 mg/1
Tablet, film coatedOral200 1/1
Tablet, film coatedOral400 mg/301
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral400 mg/400mg
Tablet, film coatedOral600 mg/1
Tablet, film coatedOral600 mg/600mg
Tablet, film coatedOral800 mg/1
Tablet, film coatedOral800 mg/800mg
CapsuleOral200 mg/1
Tablet, sugar coatedOral
Tablet, chewableOral100 mg/1
Capsule, liquid filledOral
Tablet, coatedOral
SuspensionOral40 mg
Tablet, chewableOral100 mg
Tablet, coatedOral100 mg/1
TabletOral100 mg
SolutionIntravenous10 mg/mL
Injection, solutionIntravenous5 mg/ml
LiquidOral50 mg/1.25mL
TabletOral600 mg/1
TabletOral200 mg/1
TabletOral400 mg
KitOral
TabletOral400 mg/537mg
Tablet, sugar coatedOral200 mg/1
Tablet, film coatedOral200 1/2001
Tablet, film coatedOral256 mg/1
CreamTopical
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Neoprofen 20 mg/2 ml vial304.5USD ml
Caldolor 400 mg/4 ml vial2.21USD ml
Caldolor 800 mg/8 ml vial1.58USD ml
Nuprin arthritis patch1.11USD patch
Ibuprofen powder1.04USD g
Nuprin muscle & joint patch1.03USD patch
Profen II 45-800 mg 12 Hour tablet0.69USD tablet
Motrin 800 mg tablet0.59USD tablet
Advil allergy sinus caplet0.5USD caplet
Ibu-drops 40 mg/ml suspension drops0.42USD ml
Motrin 600 mg tablet0.4USD tablet
Ibuprofen 800 mg tablet0.36USD tablet
Ibuprofen 400 mg tablet0.35USD tablet
Infant's motrin 50 mg/1.25 ml0.34USD ml
Childs ibuprofen susp drp0.33USD ml
Ibuprofen 600 mg tablet0.33USD tablet
Wal-profen cold & sinus cplt0.3USD caplet
Infant ibuprofen susp drop0.29USD ml
Motrin 400 mg tablet0.29USD tablet
CVS Pharmacy infant ibuprofen susp drop0.25USD ml
Infants medi-profen susp0.23USD ml
Advil cold & sinus caplet0.22USD caplet
Advil pm caplet0.22USD caplet
Soba profen cold-sinus tablet0.22USD tablet
Midol caplet0.21USD caplet
Advil migraine 200 mg capsule0.2USD capsule
Ibuprofen cold-sinus caplet0.2USD caplet
Motrin 100 mg caplet0.2USD caplet
Motrin pm caplet0.2USD caplet
Advil 200 mg liqui-gel capsule0.19USD capsule
Soba profen ib caplet0.19USD caplet
Motrin 100 mg tablet chew0.18USD tablet
Pub infants profenib drops0.18USD ml
Sm ibuprofen ib 100 mg tablet0.18USD tablet
Eck ibuprofen jr caplet0.17USD caplet
Ibuprofen pm caplet0.17USD caplet
Advil 200 mg caplet0.15USD capsule
Advil 200 mg gel caplet0.15USD caplet
Advil 200 mg tablet0.15USD tablet
Ibuprofen 100 mg tablet chew0.15USD tablet
Motrin ib 200 mg caplet0.15USD caplet
Apo-Ibuprofen 600 mg Tablet0.14USD tablet
CVS Pharmacy ibuprofen jr str 100 mg tablet0.14USD tablet
Nu-Ibuprofen 600 mg Tablet0.14USD tablet
Motrin ib 200 mg tablet0.13USD tablet
Motrin ib 200 mg gelcap0.12USD capsule
Nuprin 200 mg caplet0.12USD caplet
Wal-profen 200 mg caplet0.12USD caplet
Wal-profen 200 mg tablet0.12USD tablet
Eql ibuprofen 200 mg tablet0.1USD tablet
Nuprin 200 mg tablet0.1USD tablet
Apo-Ibuprofen 400 mg Tablet0.08USD tablet
Ibuprofen ib 200 mg tablet0.08USD tablet
Novo-Profen 400 mg Tablet0.08USD tablet
Apo-Ibuprofen 300 mg Tablet0.07USD tablet
Medi-profen 200 mg tablet0.07USD tablet
Ibuprofen 100 mg/5ml Suspension0.06USD ml
Ibuprofen 200 mg caplet0.06USD caplet
Child ibuprofen susp0.05USD ml
Children's medi-profen susp0.05USD ml
Children's motrin cold suspension0.05USD ml
CVS Pharmacy ibuprofen 200 mg tablet0.05USD tablet
Ibuprofen cold suspension0.05USD ml
I-prin 200 mg tablet0.05USD tablet
Novo-Profen 600 mg Tablet0.05USD tablet
Children's motrin cold0.04USD ml
Pv ibuprofen 200 mg caplet0.04USD caplet
Soba children's profenib susp0.04USD ml
Ibuprofen 200 mg tablet0.03USD tablet
CVS Pharmacy ibuprofen 200 mg caplet0.02USD caplet
Pv ibuprofen 200 mg tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5215755No1993-06-012010-06-01Us
US6599531No1997-06-102017-06-10Us
US6348216No1997-06-102017-06-10Us
US6342530No2000-11-142020-11-14Us
US6344479No2001-03-202021-03-20Us
US8415337No2012-03-022032-03-02Us
US6211246No1999-06-102019-06-10Us
US8883849No2002-01-172022-01-17Us
US9155718No2002-01-172022-01-17Us
US8263647No2002-05-302022-05-30Us
US7863287No2007-02-282027-02-28Us
US6251426No1998-06-252018-06-25Us
US6727286No2001-11-272021-11-27Us
US8735452No2009-09-302029-09-30Us
US9138404No2009-09-302029-09-30Us
US9114068No2009-09-302029-09-30Us
US8871810No2009-09-302029-09-30Us
US9012508No2010-09-142030-09-14Us
US9295639No2009-09-302029-09-30Us
US8067451No2006-07-182026-07-18Us
US8501228No2006-07-182026-07-18Us
US8318202No2006-07-182026-07-18Us
US8449910No2006-07-182026-07-18Us
US8309127No2006-07-182026-07-18Us
US8067033No2006-07-182026-07-18Us
US9649284No2009-09-302029-09-30Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)75-77.5U.S. Patent 3,228,831 U.S. Patent 3,385,886
water solubility21 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.97AVDEEF,A (1997)
logS-3.99ADME Research, USCD
Caco2 permeability-4.28ADME Research, USCD
pKa4.91SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0684 mg/mLALOGPS
logP3.5ALOGPS
logP3.84ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)4.85ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity60.73 m3·mol-1ChemAxon
Polarizability23.76 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9619
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.759
P-glycoprotein inhibitor INon-inhibitor0.9705
P-glycoprotein inhibitor IINon-inhibitor0.9323
Renal organic cation transporterNon-inhibitor0.9323
CYP450 2C9 substrateNon-substrate0.7594
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6877
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9305
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9881
CYP450 3A4 inhibitorNon-inhibitor0.9655
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9691
Ames testNon AMES toxic0.9894
CarcinogenicityCarcinogens 0.5553
BiodegradationReady biodegradable0.5142
Rat acute toxicity2.3092 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9719
hERG inhibition (predictor II)Non-inhibitor0.9734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (11.4 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)GC-MSsplash10-02t9-1910000000-23f448d7be7d5cc35682
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)GC-MSsplash10-02t9-1910000000-cbe52d63986b68a2cec0
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)GC-MSsplash10-00di-9300000000-cc259b7768023e4cdba8
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-03di-3910000000-618880f8fd7b8ec3d473
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-02t9-1910000000-23f448d7be7d5cc35682
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-02t9-1910000000-cbe52d63986b68a2cec0
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00di-9300000000-cc259b7768023e4cdba8
Mass Spectrum (Electron Ionization)MSsplash10-03xr-3900000000-e20ef3c30496e17720ba
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-03di-0910000000-90bf6813134491c9fbfd
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-001i-9800000000-56f599abc462380b648c
MS/MS Spectrum - EI-B (HITACHI RMU-6E) , PositiveLC-MS/MSsplash10-03di-3910000000-618880f8fd7b8ec3d473
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-1900000000-f1b7a986fee133d97eb1
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0920000000-aa36b3244e32560bb9d5
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Phenylpropanoic acids
Sub Class
Not Available
Direct Parent
Phenylpropanoic acids
Alternative Parents
Monocyclic monoterpenoids / Aromatic monoterpenoids / Phenylpropanes / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
2-phenylpropanoic-acid / P-cymene / Aromatic monoterpenoid / Monocyclic monoterpenoid / Monoterpenoid / Phenylpropane / Monocyclic benzene moiety / Benzenoid / Monocarboxylic acid or derivatives / Carboxylic acid
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid (CHEBI:5855)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther. 2003 Mar;25(3):817-51. [PubMed:12852704]
  2. Ouellet M, Falgueyret JP, Percival MD: Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. Biochem J. 2004 Feb 1;377(Pt 3):675-84. [PubMed:14510637]
  3. Gallego-Sandin S, Novalbos J, Rosado A, Gisbert JP, Galvez-Mugica MA, Garcia AG, Pajares JM, Abad-Santos F: Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: correlation with endoscopic lesions and adverse reactions. Dig Dis Sci. 2004 Sep;49(9):1538-44. [PubMed:15481334]
  4. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, Johnson DH, Morrow JD: Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 2004 Nov 15;334(2):266-75. [PubMed:15494133]
  5. Sanchez-Fidalgo S, Martin-Lacave I, Illanes M, Motilva V: Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. Eur J Pharmacol. 2004 Nov 28;505(1-3):187-94. [PubMed:15556152]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther. 2003 Mar;25(3):817-51. [PubMed:12852704]
  2. Patrignani P: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res. 2003 Jun 15;110(5-6):281-6. [PubMed:14592549]
  3. Gupta K, Kaub CJ, Carey KN, Casillas EG, Selinsky BS, Loll PJ: Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2004 Feb 9;14(3):667-71. [PubMed:14741265]
  4. Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. [PubMed:14987823]
  5. Hillarp A: [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]. Lakartidningen. 2004 Nov 4;101(45):3504-6, 3508-9. [PubMed:15575422]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. [PubMed:23536207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Modulator
General Function
Ubiquitin protein ligase binding
Specific Function
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appea...
Gene Name
BCL2
Uniprot ID
P10415
Uniprot Name
Apoptosis regulator Bcl-2
Molecular Weight
26265.66 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Modulator
General Function
Transmembrane signaling receptor activity
Specific Function
Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C ...
Gene Name
THBD
Uniprot ID
P07204
Uniprot Name
Thrombomodulin
Molecular Weight
60328.72 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Serine-type endopeptidase activity
Specific Function
Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in t...
Gene Name
PLAT
Uniprot ID
P00750
Uniprot Name
Tissue-type plasminogen activator
Molecular Weight
62916.495 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Transporter activity
Specific Function
FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. Binds satu...
Gene Name
FABP2
Uniprot ID
P12104
Uniprot Name
Fatty acid-binding protein, intestinal
Molecular Weight
15207.165 Da
References
  1. Velkov T, Chuang S, Wielens J, Sakellaris H, Charman WN, Porter CJ, Scanlon MJ: The interaction of lipophilic drugs with intestinal fatty acid-binding protein. J Biol Chem. 2005 May 6;280(18):17769-76. Epub 2005 Feb 18. [PubMed:15722357]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li S: A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi: 10.1523/JNEUROSCI.5045-09.2010. [PubMed:20089905]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Pdz domain binding
Specific Function
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO...
Gene Name
CFTR
Uniprot ID
P13569
Uniprot Name
Cystic fibrosis transmembrane conductance regulator
Molecular Weight
168139.895 Da
References
  1. Devor DC, Schultz BD: Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion. J Clin Invest. 1998 Aug 15;102(4):679-87. [PubMed:9710435]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Omkvist DH, Trangbaek DJ, Mildon J, Paine JS, Brodin B, Begtrup M, Nielsen CU: Affinity and translocation relationships via hPEPT1 of H-X aa-Ser-OH dipeptides: evaluation of H-Phe-Ser-OH as a pro-moiety for ibuprofen and benzoic acid prodrugs. Eur J Pharm Biopharm. 2011 Feb;77(2):327-31. doi: 10.1016/j.ejpb.2010.12.009. Epub 2010 Dec 13. [PubMed:21147219]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 Feb 7;272(6):3406-10. [PubMed:9013583]

Enzymes

Details
1. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF: New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. [PubMed:20167001]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Carlile DJ, Hakooz N, Bayliss MK, Houston JB: Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol. 1999 Jun;47(6):625-35. [PubMed:10383540]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. [PubMed:23536207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
Gene Name
UGT2B4
Uniprot ID
P06133
Uniprot Name
UDP-glucuronosyltransferase 2B4
Molecular Weight
60512.035 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Yamasaki K, Rahman MH, Tsutsumi Y, Maruyama T, Ahmed S, Kragh-Hansen U, Otagiri M: Circular dichroism simulation shows a site-II-to-site-I displacement of human serum albumin-bound diclofenac by ibuprofen. AAPS PharmSciTech. 2000 May 14;1(2):E12. [PubMed:14727845]
  2. Galantini L, Leggio C, Konarev PV, Pavel NV: Human serum albumin binding ibuprofen: a 3D description of the unfolding pathway in urea. Biophys Chem. 2010 Apr;147(3):111-22. doi: 10.1016/j.bpc.2010.01.002. Epub 2010 Jan 18. [PubMed:20117876]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. Epub 2005 Jan 7. [PubMed:15640378]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  3. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697]
  4. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  3. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  2. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34